New shot for eczema shows promise in early trial

NCT ID NCT07211542

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SHR-1905 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Half will get the drug, half a placebo, and neither they nor their doctors will know who got what. The main goal is to see if the drug can reduce eczema severity by at least 75% after a set time. Researchers will also check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1905 injection
What this could lead to: If successful, this could point toward a new treatment option for people with moderate-to-severe atopic dermatitis, potentially reducing skin inflammation and itch.
What could go wrong: This is an early Phase IIa study with only 75 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Locations

Dermatology Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510091, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.